Features
Why Choose BONTAC?
Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
The reduced form of β-nicotinamide mononucleotide (β-NMN) is called β-nicotinamide mononucleotide disodium salt, or β-NMN disodium salt. It is a salt form of β-NMN, in which two sodium ions are bonded to the molecule. The disodium salt form can be more stable and easier to handle than the free acid form. It is also known as β-Nicotinamide Mononucleotide disodium, β-NMN disodium, and disodium β-Nicotinamide Mononucleotide.
Featured Products
Collection about BONTAC
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
Our updates and blog posts
Delving into the Function of Ginsenoside Rh2 in the Develpoment of Breast Cancer
1. Introduction According to the 2020 report of World Health Organization (WHO), there are approximately 2.3 million cases with breast cancer worldwide. Breast cancer has emerged as one of the most malignant tumor in females with significant incidence rate. Although great progress has made in improving the cure rate of early-stage breast cancer in recent years, advanced breast cancer is still hard to be cured. How to reduce the risk of recurrence and metastasis of early-stage breast cancer as well as prolong the survival of patients with advanced breast cancer is still a challenge in the clinical treatment of breast cancer. Notably, ginsenoside Rh2 (GRh2) exerts prominent impacts on retarding the progression of breast cancer via strengthening the immune surveillance of natural killer (NK) cells, a kind of cytotoxic innate lymphocytes critical for tumor immune response. 2. The repressive role of GRh2 in the progression of breast cancer GRh2 hinders the growth, proliferation and metastasis of breast cancer. Simply put, the body weight and tumor volume of model mice are markedly reduced post treatment of GRh2 (10 mg/kg and 20 mg/kg). In addition, the proliferating rate of breast cancer cells is repressed by GRh2 in a dose-dependent manner (5, 10 and 20 mg/kg). Upon the treatment of GRh2 (20 mg/kg), the loss of lung capacity is obviously reduced and the lung metastases formed by MDA-MB-231 tumor cells are strikingly mitigated as well, with no apparent liver metastatic nodules. 3. The enhanced killing effect of NK cells on breast cancer cells following GRh2 treatment GRh2 exerts remarkable effects on retarding the progression of breast cancer via improving the killing ability of NK92MI cells. In a nutshell, the mRNA expression levels of killing mediators perforin and IFN-γ in NK92MI cell-breast cancer cell co-culture system are explicitly upregulated post GRh2 treatment. Strikingly, the reduced lung metastasis of breast cancer by GRh2 is almost counteracted upon the depletion of NK cells. Relative to that of the vehicle control, the amount of CD107a, a degranulation marker of NK cells, is overtly elevated in the presence of GRh2 (20 mg/kg), verifying the enhanced killing activity of NK cells on breast cancer. 4. The underlying molecular mechanism of GRh2 on potentiating the NK cell activity against breast cancer Breast cancer cells reduce the recognition by NKG2D through proteolytic shedding MICA mediated by ERp5 to escape NK cell surveillance. GRh2 interferes with the formation of soluble MICA (sMICA) by suppressing the expression of ERp5 to increase the contents of killing mediators from NK cells, thereby exerting striking effects on fighting against breast cancer. 5. Conclusion GRh2 potentiates the cytotoxic effect of NK cells and enhances the immune surveillance function of NK cells to fight against breast cancer, which may be a potent drug candidate for the prevention and treatment of breast cancer. Reference [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 [2] Yang C, Qian C, Zheng W, et al. Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer. Phytomedicine. 2024;123:155180. doi:10.1016/j.phymed.2023.155180 Product advantages of BONTAC ginsenoside Rh2 BONTAC is the first enterprise worldwide that can provide national mass production of ginsenosides (Rh2) by enzymatic synthesis, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
Health Food Expo, Ingredients and Contract Manufacture 2024 is approaching
On April 24th-25th 2024, Health Food Expo, Ingredients and Contract Manufacture 2024 will be held in Tokyo International Exhibition Hall, Japan. Dr Cheung, the chief scientist and founder of BONTAC, is invited to deliver a speech themed by Independent Wholechain Technology for Coenzyme Synthesis at this exhibition. BONTAC will display patent-grade raw materials for enzymes and natural products at Booth No. A15. See you there for more surprises! About Dr. Cheung Dr Cheung, the chief scientist and founder of BONTAC, was once engaged in research work at the Institute of Genetics and Developmental Biology in Chinese Academy of Sciences, Cornell University and City University of Hong Kong. She has been dedicated to the application of biological enzyme catalysis technology into the green bio-manufacturing industrialization of coenzymes, medical intermediates and natural products for over 20 years. Notably, Dr. Cheung has applied approximately 90 invention patents at home and abroad, authorized over 60 patents and conducted key R&D plan projects in Guangdong province as well as key science and technology projects in Shenzhen city. BONTAC Product List Niche Area Products Application Scope NMN (CAS No.: 1094-61-7) Healthcare products; Cosmetics; Medicine NAD (CAS No.: 53-84-9) Healthcare products; Cosmetics; Diagnostic reagents Raw materials for enzyme catalysis; Animal health Coenzyme Endotoxin-free grade NADH (CAS No.: 606-68-98) Functional food and drink; Biomedical research and development Healthcare product; Diagnostic reagents NADP (CAS No.: 24292-60-2/1184-16-3) Raw materials for medicine or enzyme catalysis; Diagnostic reagents; In vitro diagnostic reagents (GR); Biomedical research and development S-NAD (CAS No.: 4090-29-3) Biochemical diagnostic reagents NR (CAS No.: 23111-00-4) Healthcare products; Cosmetics; Diagnostic reagent Natural products Ginsenoside Rh2(CAS No.：78214-33-2) Healthcare products; Cosmetics; Drink; Alcohol; Medicine; Functional food Ginsenoside Rg3(Cas No. : 38243-03-7) Salidroside (Cas No.: 10338-51-9) Healthcare products; Scientific research experiment; New drug development Stevia Sweetener (RD)(Cas No.: 63279-13-0 ) Food; Drink; Daily chemical industry; Brewing Raw materials for cosmetics Pro-Xylane (CAS No.: 439685-79-7) Cosmetics Erythrothioneine Cosmetics Dietary supplements L-Glutathione Reduced Healthcare products; Cosmetics Resveratrol Healthcare products; Cosmetics Phosphatidylserine Healthcare products; Biochemical diagnostic reagent Medicine and intermediate Ursodeoxycholic acid(CAS No.: 128-13-2) Healthcare products; Biochemical diagnostic reagent Chenodeoxycholic acid Healthcare products; Biochemical diagnostic reagent Cholic acid Healthcare products; Biochemical diagnostic reagents BONTAC profile Bontac Bio-Engineering (Shenzhen) Co., Ltd. (also referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales. There are six major series of product in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates. BONTAC is the pioneer of NMN industry. By virtue of the first whole-enzyme catalysis technology in China, BONTAC takes the industry lead in its niche field of coenzyme. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents.
Potential Treatment for Glaucoma: NAD+ Precursor NR
Introduction Glaucoma is regarded as the second dominant cause of blindness across the world. With the amounting number and proportion of elderly people, it is estimated that 111.8 million people will have glaucoma by 2040. Nicotinamide riboside (NR) has been attested to protect retinal ganglion cells from the stress of elevated intraocular pressure and optic nerve crush. Glaucoma patients can protect their optic nerves by oral administration of NR at a dose of 300 mg (approximately 1.18 mM). The abovementioned protective effects of NR may be achieved by its antioxidant and antifibrotic properties. About glaucoma Glaucoma is a typical ocular disease characterized by atrophy and depression of the optic nerve head, visual field defects, and diminution of vision. The pathologically increased intraocular pressure and insufficient blood supply to the optic nerve are deemed as the primary risk factors for the development of the disease. In addition to those with family history of glaucoma, people with severe myopia/hyperopia, hypertension, hyperlipidemia, hyperglycemia and long-term use of corticosteroid medications, especially eye drops, are at high risk for glaucoma. Extraordinary role of NR in protecting HTMs against oxidative stress In glaucoma, oxidative stress can trigger TM degeneration, thereby resulting in intraocular hypertension. Herein, an oxidative damage model is established in vitro by incubation of human trabecular meshwork (HTM) cells with 200 μM H2O2 for 24 h. As expected, NR hampers H2O2-induced apoptosis in HTM cells, as evidenced by the upregulation of the anti-apoptotic protein Bcl-2 and downregulation of apoptotic protein Bax. Conversely, NR boosts the viability of oxidative-damaged HTM cells. In addition, NR can shield HTM cells from oxidative stress by lowering ROS and superoxide anion levels. Apart from this, NR overtly improves the H2O2-induced decrease in the mitochondrial membrane potential (MMP) in HTM cells, hinting its antioxidant effect possibly achieved by maintaining mitochondrial homeostasis. Underlying mechanism regarding the antioxidant role of NR in HTM cells MAPK and JAK2/Stat3 pathways are related to NR-alleviated HTM cell apoptosis during oxidative stress. In the MAPK pathway, H2O2 leads to the downregulation of p-P38/P38 ratio and upregulation of p-ERK1/2 protein expression, which are offset by intervention with NR. In the JAK2/Stat3 pathway, H2O2 induces downregulation of p-JAK2 protein expression, while NR runs oppositely. Potential antifibrotic role of NR in HTM cells Considering that transforming growth factor-beta 2 (TGF-β2), a profibrotic cytokine, is also a major contributor to glaucomatous HTM dysfunction, an HTM cell model of fibrosis is constructed by induction of TGF-β2 at 10 ng/mL for 48 h. Remarkably, NR prevents TGF-β2-induced fibrosis by reducing extracellular matrix (ECM) deposition in HTM cells. Concretely, the mRNA and protein levels of fibronectin (FN) are elevated in the TGF-β2-treated HTM cells, which however are counteracted by NR. Conclusion NR can boost the viability, proliferation and MMP oxidative damage in H2O2-induced HTM cells, and hamper TGF-β2-induced fibrosis, which is linked to the MAPK and JAK2/Stat3 pathways. NR may be a potential therapeutic agent for glaucoma by inhibiting oxidative damage and fibrosis in HTM cells. Reference Zeng Y, Lin Y, Yang J, et al. The Role and Mechanism of Nicotinamide Riboside in Oxidative Damage and a Fibrosis Model of Trabecular Meshwork Cells. Transl Vis Sci Technol. 2024;13(3):24. doi:10.1167/tvst.13.3.24 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, or costs resulting or arising directly or indirectly from your reliance on the information and material on this website.